Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3

被引：0
|
作者：
Leypoldt, L. [1 ]
Callander, N. S. [2 ]
Richardson, P. G. [3 ]
Hus, M. [4 ]
Ribrag, V. [5 ]
Lopez, J. M. [6 ]
Kim, K. [7 ]
Lee, J. H. [8 ]
Dimopoulos, M. A. [9 ,10 ]
Schjesvold, F. [11 ,12 ]
Facon, T. [13 ]
Jo, J. -C. [14 ]
Min, C. -K. [15 ]
Mielnik, M. [4 ]
Cheng, S. [16 ]
Smith, L. M. [16 ]
Breitbach, C. J. [16 ]
Brawley, C. [17 ]
Sembhi, H. [17 ]
LaMacchia, J. [18 ]
Grosicki, S. [19 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Katedra & Klin Hematoonkol & Transplantacji Szpik, Lublin, Poland
[5] Inst Gustave Roussy, Villejuif, France
[6] Univ Complutense Madrid, Hosp Univ 12 Octubre, Dept Hematol, CNIO,CIBERONC, Madrid, Spain
[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[8] Gachon Univ, Gachon Univ Gil Med Ctr, Coll Med, Incheon, South Korea
[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[10] Alexandra Hosp, Athens, Greece
[11] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway
[12] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[13] Lille Univ Hosp, Dept Haematol, Lille, France
[14] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea
[15] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[16] SpringWorks Therapeut, Stamford, CT USA
[17] GSK, Stevenage, Herts, England
[18] GSK, Waltham, MA USA
[19] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P330
引用
收藏
页码：176 / 177
页数：2
相关论文
共 50 条
  • [21] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Lonial, Sagar
    Voorhees, Peter M.
    Degli Esposti, Simona
    Gupta, Ira
    Opalinska, Joanna
    Sapra, Sandhya
    Gorsh, Boris
    He, Zangdong
    Kleinman, David M.
    Schaumberg, Debra
    Loubert, Angely
    Meunier, Juliette
    Regnault, Antoine
    Eliason, Laurie
    BLOOD, 2020, 136
  • [22] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
    Trautmann-Grill, K.
    Lonial, S.
    Nooka, A. K.
    Thulasi, P.
    Badros, A. Z.
    Jeng, B. H.
    Callander, N. S.
    Sborov, D.
    Zaugg, B. E.
    Popat, R.
    Degli, Esposti S.
    Baron, J.
    Doherty, A.
    Lewis, E.
    Opalinska, J.
    Paka, P.
    Piontek, T.
    Gupta, I
    Farooq, A., V
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
  • [24] DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
    Mateos, Maria-Victoria
    Robak, Pawel
    Hus, Marek
    Fu, Chengcheng
    Zherebtsova, Vera
    Ward, Christopher
    Ho, P. Joy
    de Almeida, Ana Carolina
    Hajek, Roman
    Kim, Kihyun
    Dimopoulos, Meletios Athanasios
    Cerchione, Claudio
    Pirooz, Nicholas
    McKeown, Astrid
    Kazeem, Gbenga
    Baig, Hena
    Eccersley, Lydia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Hungria, Vania
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) plus Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Mateos, Maria Victoria
    Robak, Pawel
    Hus, Marek
    Fu, ChengCheng
    Zherebtsova, Vera
    Ward, Christopher
    Ho, P. Joy
    De Almeida, Ana Carolina
    Hajek, Roman
    Kim, Kihyun
    Dimopoulos, Meletios
    Cerchione, Claudio
    Pirooz, Nick
    McKeown, Astrid
    Kazeem, Benga
    Baig, Hena
    Eccersley, Lydia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Hungria, Vania
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S571 - S571
  • [26] Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
    Hungria, Vania
    Robak, Pawel
    Hus, Marek
    Fu, ChengCheng
    Zherebtsova, Vera
    Ward, Christopher
    de Almeida, Ana Carolina
    Ho, P. Joy
    Hajek, Roman
    Cerchione, Claudio
    Pirooz, Nick
    McKeown, Astrid
    Baig, Hena
    Eccersley, Lydia
    Pompilus, Farrah
    McNamara, Simon
    Lin, Chee Paul
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Victoria Mateos, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S568 - S568
  • [27] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [28] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante-Barrigon, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Greil, Richard
    Melchardt, Thomas
    Antonioli, Elisabetta
    Schjesvold, Fredrik
    Lysen, Anna
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    Mouro, Jorge
    D'Estrube, Tim
    Fry, Mark
    Byrne, Julie
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
  • [29] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [30] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
12345